Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSL1 | P33121 | 10/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ACACB | O00763 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26780280 | 0.91 | ACSL1 (0.69) | ACSL1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL27256212 | 0.82 | ACSL1 (0.85) | ACSL1 | |
| SCHEMBL27256216 | 0.81 | ACSL1 (0.86) | ACSL1ACACB | |
| SCHEMBL27256226 | 0.81 | ACSL1 (0.60) | ACSL1 | |
| SCHEMBL19023229 | 0.80 | MAPT (0.53) | ACSL1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL27256227 | 0.80 | ACSL1 (0.86) | ACSL1 | |
| SCHEMBL27256180 | 0.80 | ACSL1 (0.86) | ACSL1 | |
| SCHEMBL27256217 | 0.77 | ACSL1 (0.71) | ACSL1ACACB | |
| SCHEMBL27256219 | 0.77 | ACSL1 (0.71) | ACSL1 | |
| SCHEMBL15000609 | 0.75 | MAPT (0.60) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | ACSL1 90/4885MAPT 2566/4885ACACB 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.